Repair Impact Fund

The REPAIR Impact Fund, established by Novo Holdings, focuses on investing in companies developing therapies targeting resistant microorganisms. The fund primarily supports early-stage development and discovery efforts in the field of antimicrobial resistance. With a clear mission to replenish the anti-infective pipeline, REPAIR typically invests in Series A and B rounds, as well as other early-stage funding opportunities.

Notable portfolio companies include Curza, IBT Vaccines, and Revagenix. The fund's investment philosophy centers on combating the growing threat of antimicrobial resistance by supporting innovative approaches to drug discovery and development. As an initiative commissioned by the Novo Nordisk Foundation and executed by Novo Holdings, REPAIR leverages extensive expertise in the healthcare and biotechnology sectors to provide value to its portfolio companies.